School of Medicine
Showing 1-13 of 13 Results
Associate Professor of Urology at the Stanford University Medical Center
Bio Dr. Jay Shah, MD is a staff surgeon and associate professor of Urology at Stanford University. He is also the Cancer Care Program Leader for Urologic Oncology at the Stanford Cancer Center. He is widely respected for his work on optimizing outcomes after surgery for bladder cancer and he lectures internationally on this topic. He is a graduate of the American Urological Association Leadership Academy and he sits on multiple national AUA committees. With a deep interest in quality improvement work, Dr. Shah is the Physician Improvement Leader for the Stanford Department of Urology and a Medical Director of the Stanford Realizing Improvement Through Empowerment (RITE) Program. Since joining the Stanford faculty in February 2017, Dr. Shah has successfully completed the Clinical Effectiveness Leadership Training (CELT) Program, the Stanford Leadership Development Program, and the Stanford Medicine Leadership Academy. His vision is to have Stanford Medicine become known for instilling leadership in all of our faculty and trainees. With this goal in mind, he has started an accredited fellowship training program in Urologic Oncology and a QI/leadership training program for urology residents. He also lectures internationally on leadership development, team building, and quality improvement.
Dr. Shah graduated magna cum laude with a degree in Biological Sciences from Harvard College. He obtained his medical degree and completed his urology residency training at Columbia University. During his time at Columbia, Dr. Shah was elected to the Alpha Omega Alpha Medical Honor Society; he was named Physician of the Year by the nursing staff; and he was recognized by the medical students with the Gold Foundation Excellence in Teaching Award. After residency, he completed a three-year fellowship in Urologic Oncology at MD Anderson Cancer Center where he earned a coveted faculty position. During his time as faculty at MD Anderson, Dr. Shah launched the bladder cancer robotics program, developed an enhanced recovery program for patients undergoing bladder removal surgery, became double board-certified in Urology and Medical Quality, and was chosen to lead the MDACC Genitourinary Center as Center Medical Director.
In his free time, Dr. Shah enjoys reading, cooking, surfing, hiking and exploring the beaches of Northern California in his Jeep Wrangler with his family and 2 dogs.
Linda M. Dairiki Shortliffe
Stanley McCormick Memorial Professor in the School of Medicine, Emerita
Current Research and Scholarly Interests The timing for intervention in obstruction in the infant and child is poorly understood.Our group has been interested in trying to define the risks that may be involved in obstructive and infectious uropathies and discovering early signs of damage to the urinary tract and kidney. We have explored ways of imaging the urinary tract using nonionizing radiation (US, MRI). We have studied the relationships of sex steroid hormones, pregnancy, reflux, urinary tract infection and urinary tract function.
Eila C. Skinner
Thomas A. Stamey Research Professor in Urology
Current Research and Scholarly Interests My research focuses on outcomes in the treatment of muscle invasive and high-grade non-muscle invasive bladder cancer. This includes identifying markers of prognosis, predictive markers for response to surgery and chemotherapy, and working toward an individualized, multidisciplinary approach to disease management. I have also focused on optimizing the use of lower urinary tract reconstruction in patients undergoing cystectomy, and developing interventions to improve patient quality of life.
Simon John Christoph Soerensen
Graduate, Medicine, Urology
Bio I am a last year medical student joining the Department of Urology from Aarhus University, Denmark. My clinical areas of interest include cancer imaging, urologic oncologic outcomes research, prostate cancer, robotic urologic surgeries, and applied deep learning in healthcare. I am currently working on developing novel deep learning methods for segmenting the prostate before MRI-TRUS fusion biopsies as well as diagnosing prostate cancer on MRI based on zonal prostate anatomy.
Eric R. Sokol, MD
Associate Professor of Obstetrics and Gynecology (Gynecology-Urogynecology) and, by courtesy, of Urology at the Stanford University Medical Center
Current Research and Scholarly Interests My research is focused on the development and testing of novel minimally invasive treatment modalities for complex pelvic floor disorders.
Assistant Professor of Urology and, by courtesy, of Radiology at the Stanford University Medical Center
Current Research and Scholarly Interests My interest is in improving prostate cancer diagnosis through MRI and image-targeted prostate biopsy. In collaboration with radiologists at Stanford, we are working to define the optimal role of MRI in prostate cancer. We hope to improve cancer imaging to the point that some men with elevated PSA may safely avoid prostate biopsy. For those who need biopsy, we are evaluating novel MRI-US fusion targeted biopsy, a technique that greatly improves upon the conventional biopsy method.
Leslee L.Subak, MD
Katharine Dexter McCormick and Stanley McCormick Memorial Professor and Professor, by courtesy, of Urology
Current Research and Scholarly Interests My research focuses on the association of weight and urinary incontinence (UI) in women and clinical trials to test strategies to improve outcomes in women’s genitourinary health. We have shown the independent association of weight and UI and the efficacy of weight loss to treat women with UI. I also conduct studies of epidemiology, economics and cost-effectiveness, and novel interventions for UI, sexual dysfunction, vaginal atrophy, pelvic organ prolapse and menopause symptoms.
Professor of Urology, Emeritus
Current Research and Scholarly Interests We focus on understanding the molecular mechanism of transcription factors that govern the transformation of normal cells to a neoplastic state. We are especially interested in nuclear hormone action and its interactions with other signaling pathways in tumor development and progression.